OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

Results From ILLUMINATE-301 To Be Discussed

Webinar To Be Held on Wednesday, March 31, 2021 at 12:00 p.m. ET.

PENNINGTON, N.J. and SAN DIEGO, March 25, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral cancer immunotherapies, today announced it will sponsor a key opinion leader (KOL) webinar to be held by LifeSci Advisors discussing the anti-PD-1 checkpoint refractory metastatic melanoma landscape and the impact of the results from ILLUMINATE-301 on Wednesday, March 31, 2021 at 12:00 p.m. ET.

The webinar features presentations by KOLs Gregory Daniels, M.D., Ph.D., UC San Diego Health, Paolo Ascierto, M.D., National Tumor Institute Fondazione G. Pascale, John M. Kirkwood, M.D., University of Pittsburgh, and Matteo Carlino, M.D., Westmead and Blacktown Hospitals.

A Fireside Chat moderated by Neil Canavan, author of "The Cure Within," will follow the formal presentations and the KOLs will be available to answer questions afterward.

To register for the event, please click here

The KOLs will discuss the anti-PD-1 checkpoint refractory metastatic melanoma landscape and commercial outlook: 

  • Gregory Daniels, M.D., Ph.D., UC San Diego Health, will lead the discussion on tumor-infiltrating lymphocytes (TILs). Dr. Daniels, a board-certified oncologist, coordinates care for patients with melanoma, skin cancers and head and neck cancers. Dr. Daniels treats certain skin cancers with highly effective immunotherapy approaches. He is part of the Precision Immunotherapy Clinic, which offers the most promising investigational immunotherapies for many types of cancer. As a professor in the Department of Medicine, Dr. Daniels is involved in training medical students, residents and fellows at UC San Diego School of Medicine. Active in research, much of his work has focused on understanding the link between autoimmunity and tumor immunity in developing more effective and less toxic immune-stimulatory approaches for patients with melanoma. Dr. Daniels completed his fellowship and residency at Mayo Clinic in Rochester, Minn. and earned his medical degree from University of Southern California Keck School of Medicine.

  • Paolo Ascierto, M.D., National Tumor Institute Fondazione G. Pascale, will co-lead the discussion on intratumoral (IT) toll-like receptor (TLR) 9. Dr. Ascierto is the Director of the Dept. of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute IRCCS Fondazione G. Pascale in Naples, Italy. He previously served as a postdoctoral fellow and then as vice-director of the Department of Clinical Immunology. His research interest has focused on diagnosis and treatment of melanoma, including assessment of new molecular markers for tumor progression, targeted therapies, immunotherapy and vaccination treatments. He has served as principal investigator in numerous clinical trials and has published numerous peer-reviewed articles on these topics. He earned his M.D. and received board-certification in oncology from the University of Naples.

  • John M. Kirkwood, M.D., University of Pittsburgh, will co-lead the discussion on intratumoral (IT) toll-like receptor (TLR) 9. Dr. Kirkwood, M.D. is board-certified in internal medicine and medical oncology and is Professor of Medicine at the University of Pittsburgh. He received his medical degree from Yale University School of Medicine, where he was also an intern and resident in internal medicine. His subspecialty is in medical oncology and he completed his fellowship in this field at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Kirkwood's early research in tumor immunology was done at Memorial Sloan Kettering and his postdoctoral fellowship work in tumor immunology at Harvard University. He is a member of the New York Academy of Sciences, the American Society for Clinical Oncology, the American Association for Cancer Research, the American Medical Association, the Eastern Cooperative Oncology Group, the National Cancer Foundation, the International Society for Interferon and Cytokine Research, the Society for Immunotherapy of Cancer, the Society for Melanoma Research, the Clinical Immunology Society and the Society of Natural Immunity.

  • Matteo Carlino, M.D., Westmead and Blacktown Hospitals, will lead the discussion on IT DNA plasmid-based Interleukin-12 (IL-12). Dr. Carlino is a Medical Oncologist at Westmead and Blacktown Hospitals, where he leads melanoma clinical trials program, a Clinical associate professor at The University of Sydney and a Faculty Member at MIA. He undertook a Ph.D. examining predictors of response and mechanisms of resistance to BRAF and MEK inhibitor treated melanoma. Dr. Carlino continues to be involved in the translational research program based at MIA and the Westmead Institute for Cancer Research. He is an investigator on multiple Phase I, II and III clinical trials in melanoma targeted and immunotherapy.

About OncoSec Medical Incorporated
OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit www.oncosec.com.

TAVO™ is a trademark of OncoSec Medical Incorporated.

Risk Factors and Forward-Looking Statements
This release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company's current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company's control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward- looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission ("SEC"). In particular, you should be aware that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, the impact of COVID-19 on the supply of our candidates or the initiation or completion of clinical trials and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC's website www.sec.gov), as well as other factors described from time to time in the Company's filings with the SEC.

Company Contact
Brian Leuthner
Chief Operating Officer

Media Contact
Patrick Bursey
LifeSci Communications

OncoSec Medical Incorporated (PRNewsfoto/OncoSec Medical Incorporated)


Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-medical-sponsoring-kol-webinar-on-a-high-unmet-medical-need-anti-pd-1-checkpoint-refractory-metastatic-melanoma-301256004.html

SOURCE OncoSec Medical Incorporated